SGLT2 inhibitors, GLP-1 agonists associated with lower mortality compared to DPP-4 inhibitors, analysis finds
Glucagon-like peptide-1 (GLP-1) agonists were associated with a higher risk of adverse events than sodium-glucose cotransporter-2 (SGLT2) inhibitors or dipeptidyl peptidase 4 (DPP-4) inhibitors, according to the meta-analysis.
Adults who were expected to have an ICU stay of at least three days and who had persistent hyperglycemia for up to six hours after admission, were receiving insulin, or both had a peripheral venous catheter placed and connected to a continuous glucose monitoring sensor.
Very low-carb diet may improve glycemic control in type 1 diabetes with few adverse events, study finds
Researchers conducted an online survey of an international social media group of people with type 1 diabetes who follow a very low-carb diet (up to 30 g/d derived from fibrous vegetables and nuts).
The software analyzes images of the eye taken with a retinal camera and offers one of two results: “more than mild diabetic retinopathy detected: refer to an eye care professional” or “negative for more than mild diabetic retinopathy; rescreen in 12 months.”
In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER
Exenatide is still an effective alternative for patients who cannot tolerate semaglutide due to gastrointestinal adverse events, noted the ACP Journal Club commentary.
An article in the May ACP Internist discusses how intensive lifestyle interventions may be able to send type 2 diabetes into remission for selected patients.